Streetbeat News

Products Services

KPTI

Onco360 has been selected as the national specialty pharmacy network partner for Karyopharm Therapeutics' XPOVIO, a first-in-class XPO-1 inhibitor approved for multiple oncology indications. XPOVIO is designed for patients with multiple myeloma and diffuse large B-cell lymphoma (DLBCL) who have undergone previous treatments. This partnership aims to enhance the distribution and accessibility of XPOVIO for patients. Karyopharm's XPOVIO has received multiple FDA approvals since 2019 for its role in inhibiting the nuclear export protein XPO-1.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:38 pm

ANIK

Anika Therapeutics projects FY24 revenue to be between $168M-$173M, below the estimated $179.42M. The company aims for accelerated profitability growth, with a focus on high-growth products. Revenue growth is expected across different product families, with OA Pain Management growing 0% to 2%, Joint Preservation and Restoration by 6% to 10%, and a decline in Non-Orthopedic by 14% to 19%. Adjusted EBITDA is anticipated to be $25M-$30M, a significant increase, reflecting cost savings and new product ramp-ups.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:35 pm

GDYN

Grid Dynamics has been awarded the AWS Well-Architected Partner Status, recognizing its capability to build and audit secure, high-performing, resilient, and efficient infrastructure for applications on AWS. This status enables Grid Dynamics to offer clients significant cost savings, faster time to market, improved application performance, and reduced security risks by leveraging a proven methodology to mitigate risks and modernize application workloads.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:11 pm

TXG

10x Genomics, Inc. (NASDAQ:TXG) has started commercial shipments of its next-generation single cell technology products, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3, powered by the new GEM-X technology. GEM-X offers enhanced performance, including up to two times more gene detection, a two-fold increase in cells captured per channel, more than two-fold reduction in cost per cell, and improved data quality. These advancements are expected to significantly benefit research in single cell and spatial biology.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:11 pm

PSTX

Poseida Therapeutics announced that the FDA has granted Orphan Drug Designation to its treatment P-BCMA-ALLO1 for Multiple Myeloma, potentially accelerating its development and approval process.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:08 pm

WS

Worthington Steel's joint venture, TWB Company, has entered into a licensing agreement with ArcelorMittal Tailored Blanks to use its ablation technology. TWB plans to install an automated ablation line at its Monroe, Michigan facility.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:02 pm

IVA

Inventiva (NASDAQ:IVA), a biopharmaceutical company, will present the results of the LEGEND Phase IIa trial on March 19, 2024. The trial evaluates lanifibranor in combination with empagliflozin for treating MASH/NASH and T2D. The study aims to assess the safety and efficacy of this combination, with primary efficacy endpoint being the change in Hemoglobin A1c at week 24. Lanifibranor, a pan-PPAR agonist, has received FDA Breakthrough Therapy and Fast Track designation for MASH/NASH treatment.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:01 pm

SLN

Four analysts have recently updated their ratings on Silence Therapeutics (NASDAQ:SLN), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $73.00, down from $75.00, with a high estimate of $75.00 and a low of $67.00. Silence Therapeutics, a biotech company, is working on therapies SLN360 and SLN124 for heart disease and anemia, respectively. Despite a strong net margin, the company has seen a revenue decline of -17.0% and has below-average ROE and impressive ROA.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:01 pm

ATEC

Alphatec Holdings (NASDAQ:ATEC) has received mixed analyst ratings over the past three months, with a positive shift in the 12-month price target to an average of $19.00, up 18.75% from $16.00. The company, specializing in spinal surgery technology, shows a strong revenue growth rate of 30.23% as of December 31, 2023, but struggles with profitability and high debt levels. Analysts from Needham and HC Wainwright & Co. maintain 'Buy' ratings with updated price targets.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:00 pm

ADBE

Adobe Inc (NASDAQ:ADBE) is set to report its Q1 financial results, with analysts expecting strong growth trends and a focus on generative AI-enabled products. Revenue is anticipated at $5.14 billion, with earnings per share at $4.38. Analysts are optimistic, citing Adobe's AI innovations and potential for increased monetization. However, there are mixed feelings about AI's impact on Adobe's existing products. The company's decision to abandon its merger with Figma and its upcoming Adobe Summit event are also key points of interest.

Portfolio Pulse from Chris Katje

March 13, 2024 | 7:18 pm